Wang C C, Mattson D, Wald A
Department of Medicine, University of Washington, USA.
Bone Marrow Transplant. 2001 Feb;27(4):445-9. doi: 10.1038/sj.bmt.1702808.
Prior studies suggest that Corynebacterium jeikeium bacteremia in immunocompromised patients results in frequent morbidity that may be decreased by prompt removal of the indwelling catheter. To summarize recent experience, charts of 53 bone marrow transplant recipients with Hickman catheters and C. jeikeium bacteremia were reviewed. Forty-one patients were treated with vancomycin without catheter removal and 10 patients underwent catheter removal with subsequent vancomycin therapy. No patient in either group died with C. jeikeium bacteremia as the proximate cause. Salvage of the intravascular catheter was successful in 38 of 41 (93%) attempts. Three patients (7%) in the catheter-salvage group and one patient (10%) in the catheter-removal group experienced recurrent bacteremia. In both catheter-salvage and catheter-removal groups, median time to negative blood culture was 2 days. Thus, time to clearance of bacteremia and patient clinical outcome did not differ between treatment groups. In many patients with Hickman catheters, C. jeikeium bacteremia may be treated successfully with vancomycin and without removal of the catheter.
先前的研究表明,免疫功能低下患者发生杰氏棒状杆菌菌血症会导致频繁发病,而及时拔除留置导管可能会降低发病率。为总结近期经验,我们回顾了53例接受骨髓移植且带有希克曼导管并发生杰氏棒状杆菌菌血症患者的病历。41例患者接受了万古霉素治疗但未拔除导管,10例患者拔除导管后接受了后续的万古霉素治疗。两组均无患者因杰氏棒状杆菌菌血症为直接病因死亡。41次保留血管内导管的尝试中有38次(93%)成功。导管保留组有3例患者(7%)和导管拔除组有1例患者(10%)发生复发性菌血症。在导管保留组和导管拔除组中,血培养转阴的中位时间均为2天。因此,治疗组之间菌血症清除时间和患者临床结局并无差异。对于许多带有希克曼导管的患者,杰氏棒状杆菌菌血症可用万古霉素成功治疗且无需拔除导管。